GemPharmatech Co Ltd
SSE:688046
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.14
20.46
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
GemPharmatech Co Ltd
Cost of Revenue
GemPharmatech Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GemPharmatech Co Ltd
SSE:688046
|
Cost of Revenue
-¥202.9m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-63%
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Cost of Revenue
-¥23.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Cost of Revenue
-¥7.7B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Cost of Revenue
-¥10.5B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Cost of Revenue
-¥4.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-32%
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Cost of Revenue
-¥1.6B
|
CAGR 3-Years
-161%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GemPharmatech Co Ltd
Glance View
GemPharmatech Co., Ltd. engages in research and development, manufacture, and sale of experimental mouse models. The company is headquartered in Nanjing, Jiangsu and currently employs 1,342 full-time employees. The company went IPO on 2022-04-25. The firm uses gene-editing and other technologies to produce mouse models. The firm also involves in the business of customized model breeding, drug efficacy analysis, and model customization. The Company’s products are mainly used to satisfy the experimental demands in the fields of gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental researches.
See Also
What is GemPharmatech Co Ltd's Cost of Revenue?
Cost of Revenue
-202.9m
CNY
Based on the financial report for Dec 31, 2023, GemPharmatech Co Ltd's Cost of Revenue amounts to -202.9m CNY.
What is GemPharmatech Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-63%
Over the last year, the Cost of Revenue growth was -35%. The average annual Cost of Revenue growth rates for GemPharmatech Co Ltd have been -40% over the past three years , -63% over the past five years .
You don't have any saved screeners yet
